Immunic to Present Nurr1 Activator Data at Neuroimmunology Summit
Event summary
- Immunic’s Chief Scientific Officer, Hella Kohlhof, will present data on vidofludimus calcium (IMU-838) at the Neuroimmunology Drug Development Summit on April 16, 2026.
- Vidofludimus calcium is a Nurr1 activator in Phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026.
- Immunic’s management and preclinical teams will attend the American Academy of Neurology (AAN) Annual Meeting in Chicago from April 18-22, 2026.
- The company’s pipeline includes earlier-stage programs like IMU-856 and IMU-381 targeting neurodegenerative and autoimmune diseases.
The big picture
Immunic's focus on oral therapies for neurologic diseases represents a significant effort to improve patient compliance and quality of life, a key unmet need in the multiple sclerosis market. The Phase 3 trial for vidofludimus calcium is a pivotal moment for the company, as success would validate its Nurr1 activation approach and potentially establish a new treatment paradigm. However, the crowded CNS drug development space and inherent risks of clinical trials mean that Immunic faces considerable challenges in achieving commercial success.
What we're watching
- Clinical Data
- The presentation at the Neuroimmunology Summit will be scrutinized for any early indications of efficacy or safety concerns with vidofludimus calcium, potentially influencing investor sentiment ahead of the Phase 3 top-line data release.
- Competitive Landscape
- The AAN meeting provides an opportunity to assess Immunic’s positioning relative to competitors in the crowded multiple sclerosis treatment market and gauge the reception of vidofludimus calcium’s unique mechanism of action.
- Pipeline Expansion
- The progress of Immunic’s earlier-stage programs, IMU-856 and IMU-381, will be critical to long-term value creation, and any updates presented at the AAN meeting could signal the breadth of their therapeutic ambitions.
Related topics